Hepion Pharmaceuticals Signs $4.38M M&A Deal with Gravitas Life Sciences, LLC
Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.
- Value
- $4.38M
- Counterparty
- Gravitas Life Sciences, LLC